Tokyo Tape
Sign in
← Immuno-Biological Laboratories

Quarterly report · Q2

4570.TEDINET S100PKP5
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥293m2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥648m2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥254m2021-04-01 → 2021-09-30Cons.Net sales
Operating income−¥55m2022-04-01 → 2022-09-30Cons.Operating income
Operating income−¥137m2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income−¥130m2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income−¥243m2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥188m2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax−¥132m2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax−¥195m2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)−¥136m2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥259m2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥199m2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income−¥136m2022-04-01 → 2022-09-30Cons.Profit loss
Net income−¥199m2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥1.6bnat 2022-09-30Cons.Assets
Total assets¥1.7bnat 2022-03-31Cons.Assets
Total assets¥1.7bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥329mat 2022-09-30Cons.Liabilities
Total liabilities¥337mat 2022-03-31Cons.Liabilities
Net assets / equity¥1.2bnat 2022-09-30Cons.Net assets
Net assets / equity¥1.4bnat 2022-03-31Cons.Net assets
Net assets / equity¥1.4bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥406mat 2022-09-30Cons.Cash and deposits
Cash and deposits¥508mat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥341mat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥449mat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥546mat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥552mat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow−¥51m2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥93m2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥100m2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥64m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥156m2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥39m2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥3m2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥144m2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥132m2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-14.622022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-8.292022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-27.782021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-21.42021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-9.512021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio78.9%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio80.2%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio81.8%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 25
SegmentItemPeriodValue
jpcrp040300-q2r_E00986-000Cosmeticsreportable segmentrevenue2022-04-01 → 2022-09-30¥2m
jpcrp040300-q2r_E00986-000Cosmeticsreportable segmentrevenue external2022-04-01 → 2022-09-30¥2m
jpcrp040300-q2r_E00986-000Cosmeticsreportable segmentsegment profit2022-04-01 → 2022-09-30−¥8m
jpcrp040300-q2r_E00986-000Gene Recombination Silkworm Developmentreportable segmentsegment profit2022-04-01 → 2022-09-30−¥41m
jpcrp040300-q2r_E00986-000Immunity Relatedreportable segmentrevenue2022-04-01 → 2022-09-30¥291m
jpcrp040300-q2r_E00986-000Immunity Relatedreportable segmentrevenue external2022-04-01 → 2022-09-30¥291m
jpcrp040300-q2r_E00986-000Immunity Relatedreportable segmentsegment profit2022-04-01 → 2022-09-30−¥6m
—segment totalrevenue2022-04-01 → 2022-09-30¥293m
—segment totalrevenue external2022-04-01 → 2022-09-30¥293m
—segment totalsegment profit2022-04-01 → 2022-09-30−¥55m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥3m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥3m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30¥480,000
jpcrp040300-q2r_E00986-000Cosmeticsreportable segmentrevenue2021-04-01 → 2021-09-30¥10m
jpcrp040300-q2r_E00986-000Cosmeticsreportable segmentrevenue external2021-04-01 → 2021-09-30¥10m
jpcrp040300-q2r_E00986-000Cosmeticsreportable segmentsegment profit2021-04-01 → 2021-09-30−¥5m
jpcrp040300-q2r_E00986-000Gene Recombination Silkworm Developmentreportable segmentsegment profit2021-04-01 → 2021-09-30−¥53m
jpcrp040300-q2r_E00986-000Immunity Relatedreportable segmentrevenue2021-04-01 → 2021-09-30¥247m
jpcrp040300-q2r_E00986-000Immunity Relatedreportable segmentrevenue external2021-04-01 → 2021-09-30¥244m
jpcrp040300-q2r_E00986-000Immunity Relatedreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥3m
jpcrp040300-q2r_E00986-000Immunity Relatedreportable segmentsegment profit2021-04-01 → 2021-09-30−¥79m
—segment totalrevenue2021-04-01 → 2021-09-30¥257m
—segment totalrevenue external2021-04-01 → 2021-09-30¥254m
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥3m
—segment totalsegment profit2021-04-01 → 2021-09-30−¥137m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 431
ItemContextValueUnit
Other caPrior1YearInstant120978000JPY
Other caCurrentQuarterInstant137024000JPY
Current assetsPrior1YearInstant1129786000JPY
Current assetsCurrentQuarterInstant1041380000JPY
LandPrior1YearInstant120081000JPY
LandCurrentQuarterInstant119277000JPY
Property plant and equipmentPrior1YearInstant120081000JPY
Property plant and equipmentCurrentQuarterInstant119277000JPY
Investment securitiesPrior1YearInstant399818000JPY
Investment securitiesCurrentQuarterInstant344336000JPY
Other ioaPrior1YearInstant55652000JPY
Other ioaCurrentQuarterInstant56623000JPY
Investments and other assetsPrior1YearInstant455471000JPY
Investments and other assetsCurrentQuarterInstant400959000JPY
Noncurrent assetsPrior1YearInstant575552000JPY
Noncurrent assetsCurrentQuarterInstant520237000JPY
AssetsPrior1YearInstant1705338000JPY
AssetsCurrentQuarterInstant1561617000JPY
Notes and accounts payable tradePrior1YearInstant3930000JPY
Notes and accounts payable tradeCurrentQuarterInstant3620000JPY
Short term loans payablePrior1YearInstant125000000JPY
Short term loans payableCurrentQuarterInstant130000000JPY
Current portion of long term loans payablePrior1YearInstant4008000JPY
Current portion of long term loans payableCurrentQuarterInstant4635000JPY
Provision for bonusesPrior1YearInstant17184000JPY
Provision for bonusesCurrentQuarterInstant21147000JPY
Other clPrior1YearInstant77960000JPY
Other clCurrentQuarterInstant63184000JPY
Current liabilitiesPrior1YearInstant228083000JPY
Current liabilitiesCurrentQuarterInstant222587000JPY
Long term loans payablePrior1YearInstant104990000JPY
Long term loans payableCurrentQuarterInstant102359000JPY
Net defined benefit liabilityPrior1YearInstant3917000JPY
Net defined benefit liabilityCurrentQuarterInstant4490000JPY
Noncurrent liabilitiesPrior1YearInstant108907000JPY
Noncurrent liabilitiesCurrentQuarterInstant106849000JPY
LiabilitiesPrior1YearInstant336990000JPY
LiabilitiesCurrentQuarterInstant329437000JPY
Capital stockPrior1YearInstant3029041000JPY
Capital stockCurrentQuarterInstant3029041000JPY
Capital surplusPrior1YearInstant2061421000JPY
Capital surplusCurrentQuarterInstant2061421000JPY
Retained earningsPrior1YearInstant-3720124000JPY
Retained earningsCurrentQuarterInstant-3856293000JPY
Treasury stockPrior1YearInstant-1990000JPY
Treasury stockCurrentQuarterInstant-1990000JPY
Shareholders equityPrior1YearInstant1368348000JPY
Shareholders equityCurrentQuarterInstant1232179000JPY
Net assetsPrior1YearInstant1368348000JPY
Net assetsCurrentQuarterInstant1232179000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass